Trials / Completed
CompletedNCT00509145
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,106 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Laquinimod | Laquinimod 0.6 mg capsule, oral, once daily |
| OTHER | Placebo | oral, once daily, capsule |
Timeline
- Start date
- 2007-11-13
- Primary completion
- 2010-11-08
- Completion
- 2010-11-08
- First posted
- 2007-07-31
- Last updated
- 2021-11-02
- Results posted
- 2021-11-02
Locations
144 sites across 24 countries: United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Poland, Romania, Russia, Serbia, Spain, Sweden, Turkey (Türkiye), Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00509145. Inclusion in this directory is not an endorsement.